Joana B. E. S.
- Country
- Portugal
- Department
- Oncology
Research Overview
- Phase 2/3 Multicenter Randomized Study of Raludotatug Deruxtecan in Platinum-Resistant High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
- Phase III Evaluation of Xevinapant and Radiotherapy Versus Placebo and Radiotherapy in High-Risk Resected Squamous Cell Carcinoma of the Head and Neck
Data & Insights
Has run more than one trial at 23 of 135 partner sites.
Specializations
Breast Oncology
Clinical research in breast cancer spans early-stage and advanced disease, with interest in hormone receptor-positive, HER2-positive, HER2-low, and triple-negative breast cancer. The portfolio also includes biomarker-defined disease such as PIK3CA-mutated and ESR1-mutated breast cancer.
- endocrine therapy
- HER2-targeted treatment
- antibody-drug conjugates
- immunotherapy
Therapeutic activity also extends to recurrence prevention and treatment intensification in locally advanced and metastatic breast malignancies.
Lung Cancer and Thoracic Malignancies
Research involvement covers non-small cell lung cancer, small cell lung cancer, and other thoracic tumors, including molecularly selected disease such as ALK-positive, EGFR-mutated, KRAS G12C-mutant, RET fusion-positive, and HER2-mutated lung cancer.
- checkpoint inhibitors
- targeted therapy
- chemoradiotherapy
- antibody-drug conjugates
Additional interests include limited-stage and metastatic settings, as well as tumors with neuroendocrine features.
Gastrointestinal and Hepatobiliary Cancers
The investigator is active in studies of gastric cancer, gastroesophageal junction adenocarcinoma, esophageal carcinoma, biliary tract cancer, and hepatocellular carcinoma. This area also includes advanced pancreatic cancer and selected colorectal cancer populations.
- immuno-oncology
- molecularly targeted treatment
- locoregional therapy
- tumor-agnostic treatment
Therapeutic interest is centered on unresectable, metastatic, and biomarker-defined gastrointestinal malignancies.
Genitourinary and Gynecologic Oncology
Clinical trial activity includes urothelial carcinoma, bladder cancer, prostate cancer, ovarian cancer, endometrial carcinoma, cervical cancer, and vulvar cancer. The scope also covers high-risk non-muscle-invasive and metastatic disease.
- hormonal therapy
- immune-based therapy
- targeted therapy
- bladder-sparing treatment
Research interests extend to biomarker-driven treatment strategies in both solid and recurrent gynecologic cancers.
Hematologic Malignancies and Cellular Therapy
Investigational work includes acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, lymphoma, myelodysplastic syndrome, and other myeloproliferative neoplasms. The portfolio also includes follow-up after gene-modified T-cell treatment.
- cellular therapy
- immunotherapy
- hematologic precision medicine
- supportive care in blood cancers
Therapeutic focus includes relapsed or refractory disease, pediatric leukemia, and long-term safety monitoring after advanced immune-based treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.